MX2021015742A - Moduladores del receptor de nmda. - Google Patents

Moduladores del receptor de nmda.

Info

Publication number
MX2021015742A
MX2021015742A MX2021015742A MX2021015742A MX2021015742A MX 2021015742 A MX2021015742 A MX 2021015742A MX 2021015742 A MX2021015742 A MX 2021015742A MX 2021015742 A MX2021015742 A MX 2021015742A MX 2021015742 A MX2021015742 A MX 2021015742A
Authority
MX
Mexico
Prior art keywords
nmda receptor
modulators
compounds
directed
inventions
Prior art date
Application number
MX2021015742A
Other languages
English (en)
Inventor
Mauro Marigo
John Paul Kilburn
Erhad Ascic
Laurent David
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2021015742A publication Critical patent/MX2021015742A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
    • B62D—MOTOR VEHICLES; TRAILERS
    • B62D15/00—Steering not otherwise provided for
    • B62D15/02—Steering position indicators ; Steering position determination; Steering aids
    • B62D15/027—Parking aids, e.g. instruction means
    • B62D15/0285—Parking performed automatically
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W30/00—Purposes of road vehicle drive control systems not related to the control of a particular sub-unit, e.g. of systems using conjoint control of vehicle sub-units
    • B60W30/06—Automatic manoeuvring for parking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W60/00—Drive control systems specially adapted for autonomous road vehicles
    • B60W60/001—Planning or execution of driving tasks
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60W—CONJOINT CONTROL OF VEHICLE SUB-UNITS OF DIFFERENT TYPE OR DIFFERENT FUNCTION; CONTROL SYSTEMS SPECIALLY ADAPTED FOR HYBRID VEHICLES; ROAD VEHICLE DRIVE CONTROL SYSTEMS FOR PURPOSES NOT RELATED TO THE CONTROL OF A PARTICULAR SUB-UNIT
    • B60W2510/00—Input parameters relating to a particular sub-units
    • B60W2510/20—Steering systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Transportation (AREA)
  • Mechanical Engineering (AREA)
  • Automation & Control Theory (AREA)
  • Epidemiology (AREA)
  • Combustion & Propulsion (AREA)
  • Human Computer Interaction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos moduladores del receptor de NMDA. Aspectos separados de las invenciones se refieren a composiciones farmacéuticas que comprenden dichos compuestos y a usos de los compuestos para tratar trastornos neurológicos o trastornos neuropsiquiátricos tales como la depresión.
MX2021015742A 2019-07-03 2020-07-01 Moduladores del receptor de nmda. MX2021015742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201900821 2019-07-03
PCT/EP2020/068522 WO2021001423A1 (en) 2019-07-03 2020-07-01 Modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
MX2021015742A true MX2021015742A (es) 2022-01-27

Family

ID=74065626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015742A MX2021015742A (es) 2019-07-03 2020-07-01 Moduladores del receptor de nmda.

Country Status (20)

Country Link
US (1) US11466027B2 (es)
EP (1) EP3994141A1 (es)
JP (1) JP2022539197A (es)
KR (1) KR20220029568A (es)
CN (1) CN114008054A (es)
AR (1) AR119340A1 (es)
AU (1) AU2020299992A1 (es)
BR (1) BR112021003928A2 (es)
CA (1) CA3144304A1 (es)
CL (1) CL2021003557A1 (es)
CO (1) CO2021017142A2 (es)
CR (1) CR20210662A (es)
EC (1) ECSP22003596A (es)
IL (1) IL289575A (es)
JO (1) JOP20210331A1 (es)
MA (1) MA56451A (es)
MX (1) MX2021015742A (es)
PE (1) PE20220137A1 (es)
TW (1) TW202116779A (es)
WO (1) WO2021001423A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
EP0743853B1 (en) 1994-02-08 2001-05-02 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
AU723349B2 (en) 1996-06-07 2000-08-24 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1998056752A1 (en) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
AU2011223976B2 (en) * 2010-03-04 2015-05-21 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor

Also Published As

Publication number Publication date
US20210002292A1 (en) 2021-01-07
TW202116779A (zh) 2021-05-01
KR20220029568A (ko) 2022-03-08
MA56451A (fr) 2022-05-11
AR119340A1 (es) 2021-12-09
CR20210662A (es) 2022-03-02
ECSP22003596A (es) 2022-02-25
JOP20210331A1 (ar) 2023-01-30
US11466027B2 (en) 2022-10-11
CO2021017142A2 (es) 2022-01-17
IL289575A (en) 2022-03-01
CN114008054A (zh) 2022-02-01
JP2022539197A (ja) 2022-09-07
WO2021001423A1 (en) 2021-01-07
CL2021003557A1 (es) 2022-08-19
BR112021003928A2 (pt) 2021-05-18
EP3994141A1 (en) 2022-05-11
CA3144304A1 (en) 2021-01-07
AU2020299992A1 (en) 2022-02-24
PE20220137A1 (es) 2022-01-27

Similar Documents

Publication Publication Date Title
BR112018013827A2 (pt) moduladores de 5?-nucleotidase, ecto e uso dos mesmos
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
MX2020013853A (es) Compuestos innovadores.
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
CR20220207A (es) Compuestos terapéuticos y métodos de uso
EA202091428A1 (ru) Замещенные амиды ii пирролидина
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
WO2020092102A3 (en) 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
CR20200346A (es) Oligonucleótidos para modular la expresión de tmem106b
CR20210662A (es) Moduladores del receptor de nmda
WO2022129047A3 (en) Modulators of the nmda receptor
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
EA202091429A1 (ru) Замещенные амиды i пирролидина
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.